Eagle Pharmaceuticals, Inc. (25)
Browse by Contract Category
Contracts
-
Amendment to Development and Licensing Agreement, by and between the Company and Robert One, LLC, dated December 9, 2022
(Filed With SEC on December 14, 2022)
-
Amended and Restated Severance Benefit Plan, effective as of December 9, 2022
(Filed With SEC on December 9, 2022)
-
Security Purchase Option Agreement, by and between the Registrant, Enalare Therapeutics Inc. and the other parties thereto, dated August 8, 2022
(Filed With SEC on August 9, 2022)
-
Announcement, dated March 28, 2022
(Filed With SEC on March 28, 2022)
-
License Agreement, dated as of August 6, 2021, between the Registrant and AOP Orphan Pharmaceuticals GmbH
(Filed With SEC on November 9, 2021)
-
Fifth Amendment to Lease Agreement between the Registrant and CAPSTONE TICE BLVD LLC. dated as of August 8, 2019
(Filed With SEC on March 2, 2020)
-
Settlement and License Agreement, by and between Teva Pharmaceuticals International GmbH
(Filed With SEC on November 9, 2022)
-
Securities Purchase Agreement, by and between the Registrant and Enalare Therapeutics Inc., dated August 8, 2022
(Filed With SEC on August 9, 2022)
-
Guaranty Agreement to Loan Agreement, by and among the Registrant, Acacia Pharma Limited and Cosmo Technologies Ltd., dated June 9, 2022
(Filed With SEC on August 9, 2022)
-
Form of Shareholder Lock-up Agreement
(Filed With SEC on March 28, 2022)
-
Lock-up Agreement, dated March 27, 2022, by and between Eagle Pharmaceuticals, Inc. and Cosmo Pharmaceuticals N.V
(Filed With SEC on March 28, 2022)
-
Form of Director Undertaking
(Filed With SEC on March 28, 2022)
-
Form of Shareholder Undertaking
(Filed With SEC on March 28, 2022)
-
Co-operation Agreement, dated March 27, 2022, by and between Eagle Pharmaceuticals, Inc. and Acacia Pharma Group plc
(Filed With SEC on March 28, 2022)
-
License Agreement, dated as of August 19, 2021, between the Registrant and Combioxin SA
(Filed With SEC on November 9, 2021)
-
Form of Performance Stock Unit Grant Package (2014 Equity Incentive Plan)
(Filed With SEC on March 5, 2021)
-
Form of Performance Stock Unit Grant Package (2014 Equity Incentive Plan)
(Filed With SEC on March 5, 2021)
-
Consulting Agreement between
(Filed With SEC on November 2, 2020)
-
Co-Promotion Agreement, dated January 7, 2020, between the Registrant and Tyme Technologies Inc
(Filed With SEC on May 11, 2020)
-
Co-Promotion Agreement with Tyme Technologies, Inc., dated January 7, 2020
(Filed With SEC on March 2, 2020)
-
Settlement Agreement, by and between the Registrant and Eli Lilly and Company, dated December 13, 2019
(Filed With SEC on March 2, 2020)
-
Description of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934
(Filed With SEC on March 2, 2020)
-
Securities Purchase Agreement, dated January 7, 2020, between the Company and Tyme
(Filed With SEC on January 8, 2020)
-
Eagle Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan
(Filed With SEC on December 16, 2019)
-
Fourth Amendment to the Exclusive License Agreement, dated April 12, 2019, by and between Eagle Pharmaceuticals, Inc., a Delaware corporation and Teva Pharmaceuticals...
(Filed With SEC on May 7, 2019)